With the aid of immunoelectrophoresis using antisera against cerebrospinal fluid (CSF), betatrace protein was found in CSF (Clausen, 1961) , in urine, and in ascitic fluid (Hochwald and Thorbecke, 1962) . Beta-trace protein has a low molecular weight of 31,000, but is one of the major CSF proteins, constituting about 700 of the total protein concentration of normal human CSF (Link, 1967) . Recently, the concentration in serum was established (Olsson, Link, and Nosslin, 1973) at about seven times lower than that in CSF.
With the aid of immunoelectrophoresis using antisera against cerebrospinal fluid (CSF), betatrace protein was found in CSF (Clausen, 1961) , in urine, and in ascitic fluid (Hochwald and Thorbecke, 1962) . Beta-trace protein has a low molecular weight of 31,000, but is one of the major CSF proteins, constituting about 700 of the total protein concentration of normal human CSF (Link, 1967) . Recently, the concentration in serum was established (Olsson, Link, and Nosslin, 1973) at about seven times lower than that in CSF.
Elevated concentrations of beta-trace protein in CSF have been found in patients with severe brain damage due to cerebrovascular disorders (Ericsson, et al., 1969; Link and Olsson, 1972) . There are also some indications of increased concentration of beta-trace protein in CSF during exacerbations of multiple sclerosis (Olsson and Link, 1973b) .
The highest amounts of beta-trace protein were found in extracts of white matter of the central nervous system (CNS); but also extracts of grey matter and of genital organs, especially epididymis, were found to contain rather high concentrations of beta-trace protein (Olsson and Link, 1973a; Olsson and Nord, 1973) .
Its high concentration in human CSF and the high amounts of beta-trace protein in white CNS medullary tumours, which not were removed. The samples were analysed for the concentration of total protein and beta-trace protein, stored at -20°C, and the quantifications performed simultaneously.
As the concentration of beta-trace protein in CSF increases with age (Link and Olsson, 1972) , a control group, consisting of CSF and serum from 19 age matched 'healthy' persons, was analysed simultaneously. These samples were obtained from patients investigated at the neurological department for minor psychoneurotic disorders-for example, tension headache. All CSF samples had a normal cell count-that is, less than five leucocytes/mm3, and a normal protein concentration-that is, less than 46 mg/100 ml up to age 45 years, thereafter increasing with age. Link (1967) . The purity of the protein was controlled by agar gel electrophoresis performed on microscopic slides, according to Wieme (1959) , under conditions previously described (Link and Muller, 1971) , where only three distinct fractions characteristic for beta-trace protein could be seen between the Y-fraction and the gamma4-globulin fraction. The protein was also tested by immunoelectrophoresis with antiserum against CSF, where one precipitation line, extending from the alpha2-region to the middle of the gamma-region was found.
Antiserum against beta-trace protein was prepared by immunization of one rabbit with the purified protein. The rabbit received 1 mg beta-trace protein mixed with 0-4 ml. physiological saline and 0-4 ml. of Freund's complete adjuvant (Difco Laboratories, Detroit, U.S.A.) injected into the toepads. Similar injections were repeated after one, two, and four months. At the two last injections, half of the dose was given. Two weeks after each of the last two injections, the rabbit was bled by ear. The antiserum thus obtained was somewhat contaminated with antibodies against IgG and gamma-trace protein, as tested by immunoelectrophoresis against human CSF and serum, but after two absorptions with human serum (antiserum and serum in proportion 1:10 at 370 C during one hour) these contaminations disappeared, and the antiserum gave only one precipitation line on immunoelectrophoresis identical with that of beta-trace protein.
METHODS

PREPARATIONS OF FRACTIONS ENRICHED IN NEURONAL
PERIKARYA AND GLIAL CELLS Neuronal and glial cell-enriched fractions were prepared, as previously described by Hamberger (1969, 1970 Moore and Perez (1968) , and by minutes at 370 C in a shaking water-bath, with vigorous shaking by hand every 10 minutes in order to ensure uniform suspension of red cells. Haemolysis was stopped by quenching in an ice-bath, and the tubes were centrifuged for five minutes at 3,000 rpm in a cold room (+40 C). The degree of haemolysis was then determined from the absorbance of the supernatant at 413 nm.
Quantification of beta-trace protein in CSF and serum was performed by single radial immunodiffusion (Mancini et al., 1964) . Ten microlitres unconcentrated CSF and 20 ,ul unconcentrated serum were applied at every determination. All analyses were carried out simultaneously. The standard for the determinations of beta-trace protein consisted of known dilutions of the purified protein that had been isolated from human CSF, as described (Link, 1967) . The lower limit for detection of beta-trace protein was 025 mg per 100 ml.
DETERMINATION OF TOTAL PROTEIN The protein concentration in standard solutions used for quantification of beta-trace protein, CSF samples, preparations of brain fractions, and CNS tumours was determined by a modification (Bailey, 1962) of the method described by Lowry et al., 1951. IMMUNOFLUORESCENCE lmmunofluorescence investigations were performed according to the multiplelayer method, described by Coons (1957 Coons ( , 1958 . Cryostat sections 5 , thick of the frozen specimens of cerebral and cerebellar monkey hemispheres were first dried and subsequently fixed in cold acetone for 30 seconds. Out of every three sections, the first was covered with antiserum against human beta-trace protein; the second was covered with antiserum against human beta-trace protein, repeatedly absorbed with the purified protein until no precipitate was seen; and the third was treated with buffered saline instead of antiserum. An The condenser was a darkfield oil immersion condenser (Carl Zeiss); the secondary filter was an OG 4 filter (Schott & Gen.). For immunofluorescence microphotographs, Gevaert Scopix G film was used, the exposure times ranging from 1 to 10 minutes.
IMMUNODIFFUSION Antiserum against human betatrace protein and the purified protein was assayed against such brain specific antigens as the S-100 protein (Moore, 1965) , the 14-3-2 protein (Moore and Perez, 1968) , and the human alpha2 glycoprotein (Warecha and Bauer, 1966) , as well as antisera against these antigens by means of double diffusion in agar plates, according to the method of Ouchterlony (1948) .
The S-100 protein and antiserum against S-100 were prepared as described by , the 14-3-2 protein and the human alpha2 glycoprotein and their antisera were generously provided by Dr 
RESULTS
With the double diffusion technique in agar, no immunological cross-reaction could be found between beta-trace protein, S-100, 14-3-2, and alpha2 glycoprotein. .
Water soluble protein recovered from grey and white CNS matter was almost identical per wet weight. The amount of water soluble betatrace protein was about three times higher in white CNS matter than in grey. Similar differences in concentration were found between both human and monkey fractions enriched in glial cells and neuronal cells. and the metastatic tumours. Also ependymomas contained lower amounts of beta-trace protein than astrocytomas and oligodendrogliomas. The ratio of the concentration of water soluble betatrace protein in astrocytomas, oligodendrogliomas, and gliomas to the other tumours was 58: 1. Three times higher values of water soluble beta-trace protein were also found in the glialcell tumours than in normal white CNS matter.
No immunofluorescence for the beta-trace protein could be seen in nerve cells of cerebral monkey cortex, although specific immunofluorescence was seen in the neuropil. As exemplified in the Figure, (a) and (b), specific immunofluorescence for the beta-trace protein was localized to cells of a morphological appearance, such as that of astrocytes and oligodendrocytes. In sections from monkey cerebellum, no immunofluorescence could be seen in Purkinje cells, whereas specific fluorescence for the betatrace protein was seen in the granular layer.
The present results from normal human nervous tissue, using quantitative studies on neuronal and glial preparations, and from normal monkey nervous tissue, using qualitative immunofluorescence studies, together with quantitative studies on pathological nervous tissue, indicate that beta-trace protein is predominantly of glial cells origin, although it is also present to some extent in the neurones. Table 4 lists the concentrations of beta-trace protein in CSF and serum and the total protein content in CSF. Significantly higher (P<O001) total protein content was found in patients with CNS tumours than in healthy controls. Within the group of patients with brain tumours, the highest concentrations of beta-trace protein were found in CSF from patients with malignant gliomas, but the values did not differ significantly from those found in CSF from patients with other brain tumours or from the controls. Significantly (P < 0'05) higher concentrations of beta-trace protein in CSF were found in patients with intraspinal tumours, especially in CSF from patients with extramedullary neurinomas. The serum concentrations of beta-trace protein were slightly higher in patients with intraspinal tumours, but did not differ significantly from patients with brain tumours or in the healthy controls.
DISCUSSION
Some years after the demonstration of beta-trace protein in CSF (Clausen, 1961; Hochwald and Thorbecke, 1962) , it could be found in extracts of human brain with the aid of immunoelectrophoresis (Laterre et al., 1964) . By means of the double immunodiffusion technique, Penny and Osserman (1971) demonstrated betatrace protein as weak precipitates in extracts of normal kidney, brain, fimbriae of Fallopian tubes, ovary, testis, and pancreas. Recently, the concentration of beta-trace protein in extracts from different human organs has been determined in relation to both the wet weight of the organ and the extracted amounts of water soluble proteins from the organ (Olsson and Nord, 1973) . This investigation shows that the highest amounts of beta-trace protein are within the white CNS matter, but that other organs, too, contain beta-trace protein in higher amounts than justifies the calling of beta-trace protein brain-specific. Especially high amounts of betatrace protein were found within the genital organs, particularly the epididymis. These measurements were performed with single radial immunodiffusion on agar, according to Mancini et al. (1964) and gave values somewhat higher than those received by the complement fixation method used in this investigation. However, the same relative differences in protein concentration between grey and white CNS matter and epididymis were obtained for both methods. The highest concentration of beta-trace protein was demonstrated in extracts of white CNS matter, whereas extracts of grey matter and epididymis contained lower, but almost equal, amounts of beta-trace protein. The high concentration in epididymis and other genital organs is obvious, but the functional importance of this is still uncertain (Olsson and Nord, 1973) .
The high concentration of beta-trace protein in CSF and the remarkable differences in concentration between human CSF and human serum make the CNS distribution of the protein as interesting as the CNS distribution of the brainspecific proteins. Many such proteins have been described during the past decade. The best known is an acidic protein, the S-100 protein (Moore, 1965) , called 'S-100' on the basis of its solubility in 100% saturated ammonium sulphate. It is only slightly smaller than beta-trace protein and has a molecular weight of 19,500-24,000 (Moore, 1969; Stewart, 1972 ). Several studies have described a glial cell origin of S-100 protein; it is also present in glial cell tumours of human brain (Hyden and McEwen, 1966; Benda, 1968; Cicero et al., 1969; Lightbody et al., 1970; Haglid and Carlsson, 1971; , although it is also claimed to be present to some extent in neurones (Hyden and McEwen, 1966; Packman et al., 1971; Sviridov et al., 1972; . In the present investigation, we found a similar cellular distribution of beta-trace protein within normal brain tissue and in different tumours. Because of this, also the concentrations of the S-100 protein earlier found by have been given in Tables 2 and 3 . The amounts of the S-100 protein were higher in the different normal brain fractions than beta-trace protein, but the proportions were almost identical.
In the brain tumours, the concentration of beta-trace protein was somewhat higher than that of S-100 protein in the tumours derived from glial cells, whereas the appearance of S-100 in other tumours was less frequent than that of beta-trace protein. This can be explained by a higher affinity of the S-100 protein to different nervous cells. S-100 is also very sparsely represented in CSF, whereas beta-trace protein is one of the major CSF proteins, indicating a higher leakage from CNS into CSF for the latter protein. The presence of beta-trace protein in tumours of a cellular origin other than glial cells might be caused by leakage into the tumour mass. The influence of CSF contamination must therefore be higher for beta-trace protein than for S-100. Although the tumours were carefully dissected from other tissues, small pieces of normal human brain could have been left at the random zone of the tumour or as islands within the tumour. Such contaminations could also explain small contents of the protein in some of the tumours not derived from glial cells.
However, the differences in amounts of betatrace protein in glial cell tumours and other tumours are quite distinct. The glial cell tumours also contained higher amounts of beta-trace protein than did normal white brain matter. This could be due to the higher density of glial cells in these tumours than in white CNS matter.
As proposed for the S-100 protein, estimates of the beta-trace protein in different tumours of the nervous system might be an aid for the evaluation of the histogenetic background of the tumour . These findings also suggest the site of synthesis. Recent studies of the synthesis of beta-trace protein within the CNS have also shown that the white CNS matter is able to produce the protein, whereas the grey CNS matter lacks this ability (Olsson and Sandberg-Wollheim, to be published).
Findings of a stronger specific immunofluorescence within white CNS matter than in grey CNS matter have been reported previously (Olsson and Nord, 1973) . A higher purity of the antiserum against beta-trace protein, used in this investigation, and some changes in the immunofluorescence technique made it possible to find specific immunofluorescence at the cellular level. The findings ofspecific immunofluorescence in astrocytes and oligodendrocytes compared with that of nerve cells is in agreement with the quantitative results from fractions enriched in glial and neuronal cells and with results achieved with extracts of tumours derived from glial cells. These results also indicate that beta-trace protein is probably synthesized by glial cells.
The higher amounts of beta-trace protein found in white CNS matter suggest that the betatrace protein is involved in glia-myelin relation as increased concentrations of beta-trace protein in CSF during exacerbations of multiple sclerosis (Olsson and Link, 1973b) and after a stroke (Ericsson et al., 1969; Link and Olsson, 1972) have been demonstrated. The sparse quantity of beta-trace protein in the peripheral nervous system (Olsson and Nord, 1973) indicates that this protein is solely involved in myelin metabolism of CNS. This may well be a reflection of embryonal derivation of Schwann cells compared with oligodendroglial cells.
The findings of considerably higher amounts of beta-trace protein within tumours of glial cells origin could only be detected in CSF as slightly higher concentrations of the protein in CSF of patients with malignant gliomas. The lack of significantly increased concentrations of beta-trace protein in CSF from patients with gliomas is possibly due to the short turnover time in CSF of beta-trace protein, recently determined at about three hours . Thus there must be very high amounts of beta-trace protein leaking from the tumour to the CSF to give significant amounts of the protein in CSF.
The significantly increased values of beta-trace protein in CSF from patients with intraspinal tumours might be due to a longer turnover time of the protein in CSF in patients with tumours that cause an incomplete or complete subarachnoidal block. The increased concentrations of beta-trace protein in CSF cannot be explained by transudation of the protein from serum to CSF, as the concentration in serum is seven times lower than in CSF .
However, even if determination of the concentration of beta-trace protein in CSF does not provide any positive information of different brain tumours, the present findings of significantly higher amounts of beta-trace protein in tumours of glial cells origin and the earlier reports of significantly higher levels of S-100 protein in astrocytomas 
